**NM signifies a non meaningful value. A dash signifies the data is not available.

NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...

Liberty Biopharma Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology.

Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial ...

Hansa Biopharma reported stronger-than-expected results for the first quarter of 2025, with earnings per share (EPS) significantly outperforming forecasts. The company posted an EPS of -0.55 ...

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.5%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology ...

Biopharma venture funding dropped 20% in the first quarter of 2025 compared to the same period the year before, according to GlobalData. Worldwide venture financing for the sector experienced a ...

Lund, Sweden, 24 April 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately.

The abstract highlights Be Biopharma’s approach using both in vitro and in vivo assays to determine the potential of B Cell Medicines (BCMs) as an allogeneic off-the-shelf cell therapy without ...